^
Association details:
| Biomarker: | TMB-H + PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non–Small Cell Lung Cancer A Meta-analysis and Individual Patient–Level Analysis
Excerpt:
...patients with concomitantly high TMB and PD-L1 expression had improved PFS (HR, 0.42; 95% CI, 0.30-0.58; P < .001) (eFigure 24 in the Supplement) and a higher complete response or partial response rate (high TMB or high PD-L1, 62.5%...Among patients with NSCLC who had undergone whole-exome sequencing, the clinical use of TMB combined with PD-L1 expression had a higher value of prediction with PFS, complete response, partial response, or DCB than TMB or PD-L1 expression alone (1-year PFS: AUC, 0.829; 3-year PFS: AUC, 0.839; ORR: AUC, 0.803; DCB: AUC, 0.740)...
DOI:
10.1001/jamanetworkopen.2019.6879.
Trial ID:
